NCT06983756View on ClinicalTrials.gov

" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

Not yet recruitingOBSERVATIONAL
Enrollment

66

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

December 1, 2025

Study Completion Date

January 1, 2026

Conditions
Erythropoietin Resistant Anemia (EPO Resistant Anemia)
Interventions
DRUG

Erythropoietin

EPO resistance

All Listed Sponsors
lead

Fayoum University

OTHER

NCT06983756 - " Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance " | Biotech Hunter | Biotech Hunter